Search Results
Sep 09, 2026, 05:00 ET Terapia de edición bases con tBE logra remisión clínica duradera en drepanocitosis y β-talasemia en varios fondos genét
significativamente entre poblaciones. El equipo desarrolló previamente la técnica tBE de ultra alta precisión Wang et al., Nat Cell Biol, 2021) para editar con precisión la región promotora de HBG1/2 en células madre hematopoyéticas autólogas obtenidas de pacientes, reactivando
More news about: CorrectSequence Therapeutics
Sep 08, 2026, 12:52 ET Cell Stem Cell: Die tBE-vermittelte Base-Editing-Therapie erzielt bei unterschiedlichen genetischen Hintergründen eine dauerhafte klinische Remission bei Sichelzellkrankheit und β-Thalassämie
Pathogene Mutationen variieren erheblich zwischen den Populationen. Das Team hatte zuvor den ultrapräzisen tBE (Wang et al., Nat Cell Biol, 2021) entwickelt, um die HBG1/2-Promotorregion in autologen, den Patienten entnommenen HSPCs präzise zu editieren und so die γ-Globin-Expression
More news about: CorrectSequence Therapeutics
Sep 08, 2026, 10:41 ET Cell Stem Cell : la thérapie d'édition de bases médiée par tBE permet d'obtenir une rémission clinique durable dans la drépanocytose et la bêta-thalassémie, quel que soit le profil génétique des patients
varient considérablement d'une population à l'autre. L'équipe avait précédemment mis au point la technique tBE (Wang et al., Nat Cell Biol, 2021), une méthode d'ultra-haute précision permettant de modifier avec précision la région promotrice HBG1/2 dans des cellules souches hématopoïétiques
More news about: CorrectSequence Therapeutics
Sep 08, 2026, 08:00 ET Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
al. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2019;92:109–117. doi: 10.1016/j.pnpbp.2019.01.002Kale H, Ganz ML, Ghosh, R. Burden of prominent anhedonia in major depressive
More news about: Johnson & Johnson
Sep 07, 2026, 20:00 ET Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds
ultra-high-precision tBE (Wang et al., Nat Cell Biol, 2021) to precisely edit the HBG1/2 promoter region in autologous HSPCs collected from patients, reactivating γ-globin expression. The
More news about: CorrectSequence Therapeutics
Sep 07, 2026, 20:00 ET Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds
ultra-high-precision tBE (Wang et al., Nat Cell Biol, 2021) to precisely edit the HBG1/2 promoter region in autologous HSPCs collected from patients, reactivating γ-globin expression. The
More news about: CorrectSequence Therapeutics
Sep 03, 2026, 07:00 ET Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
important to the development of effective phage therapies, including stability, infectivity and efficient genome delivery."The full paper (J Mol Biol. 2026 Nov 1; 438(21):169993) can be found
More news about: Armata Pharmaceuticals, Inc.
Aug 20, 2026, 13:49 ET Vascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease
https://doi.org/10.1038/s41598-024-82943-19. Cortese-Krott MM, Kelm M. Endothelial nitric oxide synthase in red blood cells: key to a new erythrocrine function? Redox Biol. 2014;2:251-258.
More news about: Vascarta Inc.
Jul 29, 2026, 07:00 ET CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
2013;123(2):887-902.Kosuru R, et al. Rap1A controls store-operated calcium entry and lung inflammation via Orai1 regulation. Arterioscler Thromb Vasc Biol. 2024;44:2271-2287.Sutton R, Garg PK, Miller J, et al. Zegocractin for acute pancreatitis with systemic inflammatory response syndrome: a randomized,
More news about: CalciMedica, Inc.
Jun 16, 2026, 10:45 ET Brain-healthy Habits for Men
Colcombe SJ, Erickson KI, Scalf PE, Kim JS, Prakash R, McAuley E, et al. Aerobic exercise training increases brain volume in aging humans. J Gerontol A Biol Sci Med Sci. 2006;61:1166–70. doi: 10.1093/gerona/61.11.1166. [
More news about: The Peanut Institute
Jun 07, 2026, 17:30 ET Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
K, Yu WH, Vincent JB.. FASEB Bioadv. 2025;7(3):e1480. doi: 10.1096/fba.2024-00151Dacquin R, Davey RA, Laplace C, et al. J Cell Biol. 2004;164(4):509–514. doi: 10.1083/jcb.200312135Centers for Disease Control and Prevention. Type 2 Diabetes. Updated May 15, 2024. Accessed
More news about: NOVO NORDISK INC.
Jun 01, 2026, 23:23 ET 中國首例鹼基編輯治療鐮貧患者持續15個月無血管閉塞危象
鐮貧」）的鹼基編輯藥物，利用由上海科技大學自主研發的自主原創的高精准變形式鹼基編輯器tBE（transformer Base Editor）（Wang et al., Nat Cell Biol, 2021），對采集的患者自體造血干細胞中的HBG1/2啟動子區域進行精准鹼基編輯，模擬健康人群中天然存在的有益鹼基突變，重新激活γ-珠蛋白的表達，從而快速提升患者胎兒血紅蛋白水平。該療法可有效抑制紅細胞鐮變，顯著減少血管閉塞危
More news about: CorrectSequence Therapeutics
May 30, 2026, 08:05 ET ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases
2025;11(8):890–899.Brennan C, Yang TJ, Hilden P, et al. A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. Int J Radiat Oncol Biol Phys. 2014;88:130–136.Garcia MA, Turner A, Brachman DG. The role of GammaTile in the treatment of brain tumors: a technical and clinical overview. J
More news about: GT Medical Technologies
May 29, 2026, 14:00 ET RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biol Ther. 2016;17(3):237-245. doi:10.1080/15384047.2016.11392354 Patil T, Mushtaq R, Marsh S, et al. Clinicopathologic characteristics,
More news about: Johnson & Johnson
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
and potent KRAS-G12C inhibitor. Cancer Research. 2021;81(13_Supplement):1259-1259. doi:10.1158/1538-7445.am2021-1259Dirican E, et al. Tumor Biol. 2016;37(6):7033-7045.Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet.
More news about: Eli Lilly and Company
May 21, 2026, 06:00 ET Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45. doi: 10.4161/15384047.2014.964087.
More news about: Innovent Biologics
May 12, 2026, 01:30 ET Kaneka Ubiquinol™與Eqology合作榮獲2026年備受矚目的Vitafoods Europe創新獎
[ii]Reynolds S。線粒體與健康。NIH 2025.Nolfi-Donegan D, et al.線粒體電子傳遞鏈。Redox Biol 2020。[iii]Kalén A, et al。大鼠和人體組織脂質成分的年齡相關變化。Lipids
More news about: Kaneka Ubiquinol™
May 06, 2026, 07:06 ET Kaneka Ubiquinol™ Wins Coveted Vitafoods Europe Innovation Award 2026 in Partnership with Eqology
[ii] Reynolds S. Mitochondria and health. NIH 2025.Nolfi-Donegan D, et al. Mitochondrial electron transport chain. Redox Biol 2020.[iii] Kalén A, et al.
More news about: Kaneka Ubiquinol™
May 06, 2026, 06:34 ET Kaneka Ubiquinol™ Wins Coveted Vitafoods Europe Innovation Award 2026 in Partnership with Eqology
[ii] Reynolds S. Mitochondria and health. NIH 2025.Nolfi-Donegan D, et al. Mitochondrial electron transport chain. Redox Biol 2020.[iii] Kalén A, et al.
More news about: Kaneka Ubiquinol™
![New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]](https://mma.prnewswire.com/media/1986460/Specialised_Therapeutics_Logo.jpg?w=300){kind=logo}
May 03, 2026, 12:00 ET New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]
2026].[10]. MacDonald KPA, Betts BC, Couriel D. Biol Blood Marrow Transplant. 2018 Jan;24(1):19-26.[11]. Bachier
More news about: Specialised Therapeutics
Mar 27, 2026, 09:00 ET Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
doi:10.1007/s13555-023-00947-74 Ultsch M, et al. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol. 2013;425(8):1330-1339. doi:10.10116/j.jmb.2013.01.0245 Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic
More news about: Eli Lilly and Company
Mar 16, 2026, 06:45 ET Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
Ultsch M, et al. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol. 2013;425(8):1330-1339. doi:10.10116/j.jmb.2013.01.0245
More news about: Eli Lilly and Company
Mar 10, 2026, 01:29 ET FDA Issues Landmark Biosimilar Guidance Incorporating Regulatory Reforms Advised by Professor Niazi: Further Cutting Development Costs by Up to 50%
https://www.regulations.gov/search?filter=fda%20niazi%20biosimilar.Niazi SK. Biosimilars: a futuristic fast-to-market advice to developers. Expert Opin Biol Ther. 2022;22(6):709-716. doi:10.1080/14712598.2022.2035212.Alira Health. 2025 Global Biosimilars Report. Alira Health; 2025.
More news about: Professor Sarfaraz K. Niazi
Feb 12, 2026, 19:00 ET Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer
[2] Tan M， Yu D. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol. 2007;608:119-129. doi:10.1007/978-0-387-74039-3_9.
More news about: Innovent Biologics
Dec 11, 2025, 09:00 ET Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
doi: 10.1101/gr.275691.121.Fang et al, Genome Biol 21, 247 (2020). https://doi.org/10.1186/s13059-020-02152-7Mundade
More news about: VolitionRx Limited